digipharm®
Home •  Site Map  •  Research  •  Reports  •  International Experts  •  Music Preparations  •  Fundamentals  •  News  •  Questions  •  Shop
digipharm®
peter huebner • micro music laboratories
M E D I C A L   R E S O N A N C E   T H E R A P Y   M U S I C®
R E D U C T I O N   O F   P S Y C H O – P H Y S I O L O G I C A L   M A N I F E S T A T I O N S   O F   S T R E S S

SCIENTIFIC RESEARCH

Research Fields Summary

Headaches

Migraine

Sleep Disorders

Pains

Neurodermatitis

Psoriasis

Medication Consumption

Dermatology

Dispersion of Stress

Faster Recovery

Mental Distress / Fear

Dizziness

Cardiovascular System

Hormone / Immune System

The Mental State

Operations

Radiation Sickness

ENT

Multiple Sclerosis

Gerontology

Diabetes

Cerebral & Nervous System

Mental & Sensory Abilities

Pediatrics

Pregnancy & Birth

Gynecology

Epilepsy

Concentration / Memory

Courage to Face Life

Creativity

Harmony

Mother & Child

Neurophysiological &
Sensory Disorders

Relaxation

Vital Energy

 

 






Scientific Studies and Clinical Observations – Summary
Health of the Regenerative System
Faster Recovery
  • Taking of fetal heart activity out of the danger zone to a very satisfactory condition.

  • Improvement of the kariopicnotic index (KPI) in risk pregnancies: in the Medical Resonance Therapy Music® group the KPI first fell to 10-12%, after 6 days to 7-8%, after 9 days to 6-8%. In the control group it first fell to 14-17%, after 6 days to 11-13%, after 9 days to 9-10% – so significantly less. The fall in the KPI shows a significant improvement in the course of the pregnancy.

  • Faster normalization of excessively high blood pressure (reduction of 15-20 mmHg) in pregnant women with mild gestosis (OPH syndrome) than in the medication group.

  • Normalization of sleep following surgery in 70%, compared to 57% in the medication group.

  • Reduction of the blood pressure in children with a tonisympathic form of vegetative angiodystonia: a positive effect was already evident by the end of the first session and had stabilized after 2 days. The general health condition improved, the number of breaths per minute changed by 1.9 breaths, the systolic vascular pressure fell an average of 6.1 mm, the diastolic vascular pressure an average of 4.0 mm. In the control group the first improvements became evident at the end of the first or the start of the second week.

  • Dispersion of the clinical risk characteristics in pregnant women with a threat of miscarriage:
    after 2-3 days there were no longer any clinical risk characteristics in 60% of the women, in 100% after 5-7 days. In the control group: the clinical risk characteristics had disappeared in 70% after 7-10 days, in 30% there was no complete dispersion of the risk characteristics.

  • Improvement in the fetal heart activity in pregnant women with gestosis (OPH syndrome): 14% faster than in the control group: the cardiotocogram showed a normalization of the condition of the fetus in 86% of the studies. After only 6 treatments the number of accelerations and the variability had increased and treatment could be completed after 12 days. In the control group normalization first occurred after 9-10 days and the entire treatment required 14 days.

  • Faster breakdown of the protein content in the urine of pregnant women with gestosis (OPH syndrome).

  • Improvement of sleep in 77% of the pregnant women with a mild form of gestosis (OPH syndrome). Reducing the frequency of sleep disorders from 86% to 7%. In the control group an increase from 50% to 80%.

  • Reduction of analgesics following gynecological surgery – in 78.6%, prolonged effectiveness of the anesthetizing and pain-killing medicine was evident, and this led to a significant reduction in quantities prescribed.

  • Taking of fetal heart activity out of the danger zone up to a level of 9.2 on the Krebs’ scale, which indicates a very satisfactory fetal condition.

  • Shorter stays in hospital:
    Normalization of the menstruation cycle – normalization of dysfunctional juvenile uterine hemorrhage: the girls could be released from hospital an average of 2 days earlier than the girls in the control group; in 75% of the girls healing actually occurred twice as fast as in the control group, and they could already go home 3 days earlier.

  • Faster normalization of high blood pressure in pregnant women than in a control group receiving hypotonic and sedative medicine.

  • Shorter stay in hospital:
    Faster recovery in pregnant women under threat of miscarriage in the first trimester of pregnancy – the women could leave the hospital successfully treated already after 9-11 days: by 35% quicker than the patients in the control group.

  • Faster recovery in high-risk pregnancies with gestosis (OPH syndrome): in this group treatment could be completed 14% faster than in the control group.

  • Faster adaptability to the new condition in children with diabetes who received insulin for the first time: 64% of a group of diabetes children adapted more quickly to their new condition than those in the control group.

  • Faster insulin process stabilization in children with diabetes: 64% of a group of diabetic children experienced a 2-3-day faster process stabilization than the children in the control group.

  • Faster recovery of pregnant women at risk with a mild form of gestosis (OPH-syndrome): Improvement in fetal heart activity: 20 - 30% faster than in the control group.
    The cardiotocogram showed a normalization of the condition of the fetus in 86% of the studies. This was also subjectively confirmed by the mothers-to-be who felt better and better. After only 6 treatments the number of accelerations and the variability of fetal heart beat had improved, documenting an improved function of the fetal-placental system. The treatment in the MRT-Music® group could be completed after 12 days, normalization in the control group first occurred after 9-10 days and the entire treatment required 14 days – that is, the recovery of the MRT-Music® group was 14% faster.

  • Improvement of sleep in 77% of the pregnant women with a mild form of gestosis (OPH syndrome). Reducing the frequency of sleep disorders from 86% to 7%. In the control group an increase from 50% to 80%.
 


  Vital Energy   For this indication please use the program:

VITAL ENERGY
 
  If you want to look at the studies in detail, please visit:
SCIENTIFIC STUDIES & CLINICAL OBSERVATIONS – COMPLETE STUDIES
With kind permission of AAR EDITION INTERNATIONAL
© 1998-  DIGIPHARM >